Fibrogen Late-Stage Pamrevlumab Pancreatic Cancer Studies Miss Endpoint

 

• Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis
• LAPIS study in locally advanced, unresectable pancreatic cancer, sponsored by FibroGen, did not meet the primary endpoint of overall survival

• Pamrevlumab was generally safe and well tolerated across both studies, with no clinically meaningful difference in overall safety vs. control arms
  

• Company to implement immediate and significant cost reduction plan in the U.S.
  
• Terminate pamrevlumab research and development (R&D) investment and expeditiously wind down remaining obligations
• Reduce U.S. workforce by approximately 75%

https://www.globenewswire.com/news-release/2024/07/30/2921378/33525/en/FibroGen-Announces-Topline-Results-from-Two-Late-Stage-Pamrevlumab-Pancreatic-Cancer-Studies-and-Provides-Corporate-Update.html